Sign inJoin waitlistJoin the waitlist

Richard Stone

Lunder Family Chair in Leukemia · Mass General Brigham

Credentials: · · · · ·

History

Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
1984–1987
Internal Medicine
Brigham and Women's Hospital
1981–1984
Harvard Medical School
1977–1981

Research

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
New England Journal of Medicine · 2006 · 2,720 citations
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
New England Journal of Medicine · 2017 · First of 29 authors · 1,902 citations

Daniel DeAngelo
147 papers
IG
Ilene Galinsky
81 papers
CB
Clara Bloomfield
80 papers
Richard Larson
76 papers
Bayard Powell
68 papers
JK
Jonathan Kolitz
65 papers
Martha Wadleigh
63 papers · 4 as a fellow
JB
John Byrd
57 papers
MT
Martin Tallman
57 papers
James Griffin
52 papers
Guido Marcucci
49 papers
DS
David Steensma
45 papers

Grants

SPORE in Leukemia
National Cancer Institute · P50
PI · $2.4M · Dana-Farber Cancer Inst
2026–2031
Development of Novel Therapeutic Strategies in Human Leukemias
National Cancer Institute · P01
Project lead · $4.4M · Dana-Farber Cancer Inst
1997–2025
SPORE in Myeloid Malignancies
National Cancer Institute · P50
PI · $10.6M · Dana-Farber Cancer Inst
2017–2023
2016 Bone Marrow Failure Disease Scientific Symposium
National Heart, Lung, and Blood Institute · R13
Contact PI · $10K · Aplastic Anemia & Mds International Fdn
2016–2017

Clinical trials

Revumenib in Combination With 7+3 + Midostaurin in AML
Principal investigator · Recruiting · Phase 1
Richard Stone, MD
2024–2028
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2018–2026
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Principal investigator · Completed · Phase 2
Arog Pharmaceuticals, Inc.
2015–2019
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Principal investigator · Completed · Phase 1, Phase 2
Daiichi Sankyo
2011–2018